Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alberto Russu
Observed names:
A Russu,
A. Russu,
Russu, Alberto
Institutions:
Bambino Gesù Children's Hospital,
Johnson & Johnson (Italy),
Istituti di Ricovero e Cura a Carattere Scientifico,
Janssen (Italy)
Observed institutions:
Janssen (Belgium),
University of Pavia,
Istituto Universitario di Studi Superiori di Pavia,
Bambino Gesù Children's Hospital,
Johnson & Johnson (Italy),
Istituti di Ricovero e Cura a Carattere Scientifico,
Janssen (Italy),
Janssen Research & Development (United States)
show all 8
ORCID:
0000-0003-2095-4365
Observed ORCID:
0000-0003-2095-4365
OpenAlex ID:
A5046754356
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
2018
·
Maarten Timmers
, Johannes Rolf Streffer
, et al.
·
Alzheimer s Research & Therapy
·
124
PDF
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
2020
·
Gerald Novak
, Johannes Rolf Streffer
, et al.
·
Alzheimer s Research & Therapy
·
117
PDF
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitor
2016
·
Maarten Timmers
, Bianca Van Broeck
, et al.
·
Alzheimer s & Dementia Translational Research & Clinical Interventions
·
65
PDF
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
2016
·
Mats O. Magnusson
, Mahesh N. Samtani
, et al.
·
Clinical Pharmacokinetics
·
36
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data
2017
·
Mats O. Magnusson
, Mahesh N. Samtani
, et al.
·
CNS Drugs
·
25
Alzheimer's disease assessment scale‐cognitive 11‐item progression model in mild‐to‐moderate Alzheimer's disease trials of bapineuzumab
2015
·
Mahesh N. Samtani
, Steven X. Xu
, et al.
·
Alzheimer s & Dementia Translational Research & Clinical Interventions
·
21
PDF
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
2018
·
Alberto Russu
, Jennifer Kern Sliwa
, et al.
·
International Journal of Clinical Practice
·
19
PDF
Prospective dose selection and acceleration of paliperidone palmitate 3‐month formulation development using a pharmacometric bridging strategy
2016
·
Mahesh N. Samtani
, Partha Nandy
, et al.
·
British Journal of Clinical Pharmacology
·
18
PDF
Evaluating Potential QT Effects of JNJ‐54861911, a BACE Inhibitor in Single‐ and Multiple‐Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration‐QTc Analysis
2018
·
Maarten Timmers
, Vikash Sinha
, et al.
·
The Journal of Clinical Pharmacology
·
11
Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression
2012
·
A Russu
, E Marostica
, et al.
·
Clinical Pharmacology & Therapeutics
·
11
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer
2023
·
Nahor Haddish‐Berhane
, Yaming Su
, et al.
·
Clinical Pharmacology & Therapeutics
·
10
PDF
Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
2016
·
Paulien Ravenstijn
, Mahesh Samtani
, et al.
·
Journal of Clinical Psychopharmacology
·
10
Stochastic model search with binary outcomes for genome-wide association studies
2012
·
A. Russu
, A. Malovini
, et al.
·
Journal of the American Medical Informatics Association
·
10
PDF
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine
2023
·
Parul Patel
, Paula Teichner
, et al.
·
Therapeutic Advances in Infectious Disease
·
9
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations
2019
·
Alberto Russu
, Adam Savitz
, et al.
·
Journal of Clinical Psychopharmacology
·
9
Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension
2024
·
Lene Nygaard Axelsen
, Anne Kümmel
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
7
PDF
Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned
2019
·
Fabiola La Gamba
, Tom Jacobs
, et al.
·
Pharmaceutical Statistics
·
7
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab
2016
·
Alberto Russu
, Mahesh N. Samtani
, et al.
·
Journal of Alzheimer s Disease
·
6
Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response
2014
·
Eleonora Marostica
, Alberto Russu
, et al.
·
Journal of Pharmacokinetics and Pharmacodynamics
·
6
Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches
2011
·
A. Russu
, I. Poggesi
, et al.
·
IEEE Transactions on Biomedical Engineering
·
6
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II)
2024
·
Huybrecht T’jollyn
, Raja Venkatasubramanian
, et al.
·
European Journal of Drug Metabolism and Pharmacokinetics
·
5
O1‐10‐05: Pharmacodynamics of the Oral Bace Inhibitor JNJ‐54861911 in Early Alzheimer's Disease
2016
·
Johannes Streffer
, Anne Börjesson-Hanson
, et al.
·
Alzheimer s & Dementia
·
4
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I)
2024
·
Huybrecht T’jollyn
, Alberto Russu
, et al.
·
European Journal of Drug Metabolism and Pharmacokinetics
·
3
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
2024
·
Alex Yu
, Anasuya Hazra
, et al.
·
Clinical Pharmacokinetics
·
3
PDF
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials
2015
·
Steven X. Xu
, Mahesh N. Samtani
, et al.
·
Alzheimer s & Dementia Translational Research & Clinical Interventions
·
3
PDF
Show more works
View as search
Works count:
54
Citation count:
558
H-index:
10
I10-index:
13
Year
Topic
Type